School of Medicine


Showing 1-10 of 13 Results

  • David Iberri

    David Iberri

    Clinical Assistant Professor, Medicine - Hematology

    BioDr. Iberri is a hematologist who specializes in the treatment of multiple myeloma, Waldenström macroglobulinemia, and other blood and bone marrow disorders. He is actively involved in clinical research evaluating novel agents in hematologic malignancies. His research interests include the development and application of biomarkers to select patients most likely to benefit from therapy, and in the development of blood tests to reduce the need for bone marrow biopsies in myeloma disease monitoring.

  • Gentaro Ikeda

    Gentaro Ikeda

    Instructor, Medicine - Cardiovascular Medicine

    BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.

  • Fumiaki Ikeno

    Fumiaki Ikeno

    Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine

    BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
    Researcher Cardiovascular Medicine, Stanford University
    Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
    Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University


    Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.

    After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.

    Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.

    Contact Information


    Falk CVRC CV007
    300 Pasteur Drive
    Palo Alto, CA 94305-5406

  • Hiroyuki Inoue

    Hiroyuki Inoue

    Postdoctoral Scholar, Cardiovascular Medicine

    BioPhysician-scientist passionate about bridging research findings and clinical practice
    - Board certified cardiologist with 10+ years clinical experience, focused on cardiovascular diseases including heart failure, ischemic heart disease, arrhythmia, and general internal medicine
    - Experience of 400+ cases as the primary operator in percutaneous coronary intervention, catheter ablation, and cardiac device implantation
    - Research expertise in extracelluler vesicles, regenerative medicine, genome editing and gene therapy

    Dr. Inoue joined the Yang lab in 2022. His research aim is the development of novel regenerative therapeutics for heart failure.

  • John P.A. Ioannidis

    John P.A. Ioannidis

    Professor of Medicine (Stanford Prevention Research), of Epidemiology and Population Health and by courtesy of Biomedical Data Science

    Current Research and Scholarly InterestsMeta-research
    Evidence-based medicine
    Clinical and molecular epidemiology
    Human genome epidemiology
    Research design
    Reporting of research
    Empirical evaluation of bias in research
    Randomized trials
    Statistical methods and modeling
    Meta-analysis and large-scale evidence
    Prognosis, predictive, personalized, precision medicine and health
    Sociology of science

  • Eric Ip

    Eric Ip

    Clinical Professor, Medicine - Primary Care and Population Health

    Current Research and Scholarly InterestsMy research interests include the use and abuse of anabolic steroids and other performance enhancing/cognitive enhancing drugs.